IRIS Institutional Research Information System - OPENBS Open Archive UniBS

PAGNESI, MATTEO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.721
NA - Nord America 2.073
EU - Europa 1.132
SA - Sud America 754
AF - Africa 79
OC - Oceania 5
Totale 6.764
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.981
SG - Singapore 1.017
CN - Cina 664
BR - Brasile 623
HK - Hong Kong 402
IT - Italia 329
VN - Vietnam 240
DE - Germania 172
FR - Francia 140
GB - Regno Unito 108
RU - Federazione Russa 98
TR - Turchia 98
FI - Finlandia 69
IN - India 61
BD - Bangladesh 56
AR - Argentina 45
CA - Canada 43
PL - Polonia 38
JP - Giappone 36
ZA - Sudafrica 33
MX - Messico 32
NL - Olanda 28
IE - Irlanda 26
SA - Arabia Saudita 25
UA - Ucraina 23
AT - Austria 22
IQ - Iraq 22
ES - Italia 20
ID - Indonesia 20
CO - Colombia 18
EC - Ecuador 18
SE - Svezia 14
PY - Paraguay 13
PK - Pakistan 12
CL - Cile 11
EG - Egitto 11
VE - Venezuela 11
CZ - Repubblica Ceca 10
MA - Marocco 10
UZ - Uzbekistan 9
AE - Emirati Arabi Uniti 8
TN - Tunisia 8
PE - Perù 7
AZ - Azerbaigian 6
KE - Kenya 6
LT - Lituania 6
BO - Bolivia 5
LV - Lettonia 5
IR - Iran 4
JM - Giamaica 4
JO - Giordania 4
NP - Nepal 4
OM - Oman 4
PA - Panama 4
PH - Filippine 4
PS - Palestinian Territory 4
SC - Seychelles 4
HN - Honduras 3
HU - Ungheria 3
IL - Israele 3
KZ - Kazakistan 3
RS - Serbia 3
SN - Senegal 3
UY - Uruguay 3
AL - Albania 2
AM - Armenia 2
AU - Australia 2
GE - Georgia 2
KG - Kirghizistan 2
LK - Sri Lanka 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
AO - Angola 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BG - Bulgaria 1
BW - Botswana 1
CH - Svizzera 1
CR - Costa Rica 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EE - Estonia 1
ET - Etiopia 1
FJ - Figi 1
GD - Grenada 1
GR - Grecia 1
GT - Guatemala 1
HR - Croazia 1
IS - Islanda 1
KH - Cambogia 1
LB - Libano 1
LU - Lussemburgo 1
MD - Moldavia 1
MM - Myanmar 1
MN - Mongolia 1
MT - Malta 1
MY - Malesia 1
PT - Portogallo 1
RO - Romania 1
SI - Slovenia 1
Totale 6.760
Salva come PNG Salva come JPEG
Città #
Singapore 511
Hong Kong 399
Ashburn 247
San Jose 217
Beijing 189
The Dalles 170
Los Angeles 112
New York 104
Lauterbourg 98
Ho Chi Minh City 96
Dallas 77
Istanbul 75
Chandler 67
Milan 61
Munich 56
Redondo Beach 54
São Paulo 54
Hanoi 46
Moscow 46
Chicago 45
Romola 44
Boardman 42
San Francisco 37
Helsinki 36
Council Bluffs 34
Tokyo 34
Frankfurt am Main 32
Buffalo 31
London 31
Orem 28
Shanghai 27
Dublin 26
Princeton 24
Montreal 23
Warsaw 23
Brooklyn 22
Santa Clara 21
Brescia 19
Denver 19
Poplar 19
Rome 19
Boston 16
Guangzhou 16
Johannesburg 16
Lappeenranta 16
Nuremberg 16
Chennai 15
Haiphong 15
Amsterdam 14
Mexico City 14
Stockholm 14
Düsseldorf 13
Phoenix 13
Turku 13
Riyadh 12
Brasília 11
Rio de Janeiro 11
Ankara 10
Atlanta 10
Changsha 10
Curitiba 10
Quito 10
Vienna 10
Charlotte 9
Houston 9
Manaus 9
Ribeirão Preto 9
Tianjin 9
Toronto 9
Biên Hòa 8
Salt Lake City 8
Belo Horizonte 7
City of London 7
Da Nang 7
Hangzhou 7
Medellín 7
New Delhi 7
Querétaro 7
Strasbourg 7
Tashkent 7
Thái Bình 7
Asunción 6
Baku 6
Brno 6
Campina Grande 6
Campinas 6
Des Moines 6
Itajaí 6
Lima 6
Manchester 6
Mumbai 6
Porto Alegre 6
Ribeirão das Neves 6
Salvador 6
West Jordan 6
Baghdad 5
Cairo 5
Cape Town 5
Caracas 5
Chengdu 5
Totale 3.849
Salva come PNG Salva come JPEG
Nome #
2024 update in heart failure 144
Advanced heart failure: guideline-directed medical therapy, diuretics, inotropes, and palliative care 109
Machine learning for prediction of in-hospital mortality in coronavirus disease 2019 patients: results from an Italian multicenter study 104
Congestion in Patients with Advanced Heart Failure: Assessment and Treatment 99
Prevalence and clinical outcomes of isolated or combined moderate to severe mitral and tricuspid regurgitation in patients with cardiac amyloidosis 98
Right ventricular to pulmonary artery coupling and outcome in patients with cardiac amyloidosis 89
Biologically active adrenomedullin as a marker for residual congestion and early rehospitalization in patients hospitalized for acute heart failure: Data from STRONG-HF 86
Vericiguat for Heart Failure with Reduced Ejection Fraction 86
Prognostic significance of serum potassium in patients hospitalized for acute heart failure 85
Telemedicine for the treatment of heart failure: new opportunities after COVID-19 85
April 2021 at a glance: focus on systolic function, quality of life and treatment in heart failure 85
Medical therapy of cardiogenic shock: Contemporary use of inotropes and vasopressors 84
Characteristics and outcomes of patients with tricuspid regurgitation and advanced heart failure 83
Sodium glucose co-transporter 2 inhibitors and quality of life in patients with heart failure: a comprehensive systematic review and meta-analysis of randomized controlled trials 83
Determinants of the protective effect of glucocorticoids on mortality in hospitalized patients with COVID-19: Insights from the Cardio-COVID-Italy multicenter study 82
Prognostic value of right ventricular longitudinal strain in patients with secondary mitral regurgitation undergoing transcatheter edge-to-edge mitral valve repair 81
Cardiac contractility modulation: an effective treatment strategy for heart failure beyond reduced left ventricular ejection fraction? 81
Clinical impact of changes in mitral regurgitation severity after medical therapy optimization in heart failure 81
High troponin levels in patients hospitalized for coronavirus disease 2019: a maker or a marker of prognosis? 79
Impact of mitral regurgitation in patients with worsening heart failure: insights from BIOSTAT-CHF 78
Sex differences in pulmonary arterial hypertension: Insights from the FOCUS-PAH registry 76
Heart failure: an update from the last years and a look at the near future 75
Frailty according to the 2019 HFA-ESC definition in patients at risk for advanced heart failure: Insights from the HELP-HF registry 74
Combined pre- and post-capillary pulmonary hypertension in left heart disease 74
Evolution of tricuspid regurgitation after transcatheter edge-to-edge mitral valve repair for secondary mitral regurgitation and its impact on mortality 73
Ventilation strategies in cardiogenic shock: Insights from the AltShock-2 registry 72
Impact of malnutrition in patients with severe heart failure 72
Organ perfusion pressure predicts outcomes in cardiogenic shock patients 72
GLP-1-ra and heart failure-related outcomes in patients with and without history of heart failure: an updated systematic review and meta-analysis 71
Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failure 70
Treating amyloid transthyretin cardiomyopathy: lessons learned from clinical trials 69
Guideline-directed medical therapy in severe heart failure with reduced ejection fraction: an analysis from the HELP-HF registry 69
Predictors and Clinical Impact of Prosthesis-Patient Mismatch After Self-Expandable TAVR in Small Annuli 69
Right ventricular thrombosis: from a case report to pathophysiology mechanisms and current treatment options 69
Clinical Impact of Renal Dysfunction in Patients with Severe Tricuspid Regurgitation and Chronic Heart Failure 67
Clinical and prognostic implications of heart failure hospitalization in patients with advanced heart failure 67
Right heart failure and mortality in patients undergoing transcatheter tricuspid valve interventions 67
Malnutrition and outcomes in patients with tricuspid regurgitation undergoing transcatheter tricuspid valve repair 67
Prognostic role of tricuspid annular plane systolic excursion/pulmonary artery systolic pressure ratio in patients hospitalized for acute heart failure 66
Predictors of optimal procedural result after transcatheter edge-to-edge mitral valve repair in secondary mitral regurgitation 66
Characteristics, treatment, and outcomes of early vs. late enrollees of the STRONG-HF trial 66
Obesity, heart failure with preserved ejection fraction, and the role of glucagon-like peptide-1 receptor agonists 66
Multimodality imaging in the diagnostic management of concomitant aortic stenosis and transthyretin-related wild-type cardiac amyloidosis 66
Titration of Medications After Acute Heart Failure Is Safe, Tolerated, and Effective Regardless of Risk 66
Burst steroid therapy and quality of life in patients with acute heart failure: Insights from the CORTAHF trial 65
Blood pressure and intensive treatment up-titration after acute heart failure hospitalization: Insights from the STRONG-HF trial 64
Medical therapy for heart failure with preserved ejection fraction: Still a minefield, but with new hope 64
Decongestion and Outcomes in Patients Hospitalized for Acute Heart Failure: Insights From the RELAX-AHF-2 Trial 64
Safety and Efficacy of Istaroxime 1.0 and 1.5 µg/kg/min for Patients with Pre Cardiogenic Shock 63
Epidemiology, pathophysiology, diagnosis and management of chronic right-sided heart failure and tricuspid regurgitation. A clinical consensus statement of the Heart Failure Association (HFA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC 63
Prognostic impact of the updated 2018 HFA-ESC definition of advanced heart failure: results from the HELP-HF registry 63
Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM-AHF trial 62
Ischemic Etiology in Advanced Heart Failure: Insight from the HELP-HF Registry 61
Transcatheter edge-to-edge mitral valve repair for post-myocardial infarction papillary muscle rupture and acute heart failure: A systematic review 60
Prognostic role of TAPSE to PASP ratio in outpatients with left ventricular systolic dysfunction 60
Prediction of Mortality and Heart Failure Hospitalization After Transcatheter Tricuspid Valve Interventions: Validation of TRISCORE 60
Incidence, Predictors, and Prognostic Impact of New Permanent Pacemaker Implantation After TAVR With Self-Expanding Valves 60
Predicting survival in patients with severe heart failure: Risk score validation in the HELP-HF cohort 60
Left atrial disease and left atrial reverse remodelling across different stages of heart failure development and progression: a new target for prevention and treatment 60
Impact of mitral regurgitation in patients with acute heart failure: insights from the RELAX-AHF-2 trial 59
Detailed Assessment of the "I Need Help" Criteria in Patients With Heart Failure: Insights From the HELP-HF Registry 59
March 2021 at a glance: focus on epidemiology, prevention and COVID-19 59
Deep phenotype characterization of hypertensive response to exercise: implications on functional capacity and prognosis across the heart failure spectrum 59
Performance of risk stratification scores and role of comorbidities in older vs younger patients with pulmonary arterial hypertension 58
Clinical burden and predictors of non-cardiovascular mortality and morbidity in advanced heart failure 58
Prognostic Benefit of New Drugs for HFrEF: A Systematic Review and Network Meta-Analysis 57
Optimization of Evidence-Based Heart Failure Medications After an Acute Heart Failure Admission: A Secondary Analysis of the STRONG-HF Randomized Clinical Trial 57
Towards a phenotype profiling of the patients with heart failure and preserved ejection fraction 55
Mapping of current practices of palliative care for patients with heart failure throughout Europe: A scoping review 54
Assessing aortic flow with doppler echocardiography in cardiogenic shock: A crucial diagnostic tool 54
Differential biomarker expression in heart failure patients with and without mitral regurgitation: Insights from BIOSTAT-CHF 54
Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial 53
Functional Mitral Regurgitation and Heart Failure With Preserved Ejection Fraction: Clinical Implications and Management 53
Changes in Liver Function Tests, Congestion, and Prognosis After Acute Heart Failure: The STRONG-HF Trial 53
Characteristics, Prognosis and ESC/ERS Risk Stratification in Obese Patients with Pulmonary Arterial Hypertension (PAH) 52
NT-proBNP and high-intensity care for acute heart failure: the STRONG-HF trial 51
Uptitrating Treatment After Heart Failure Hospitalization Across the Spectrum of Left Ventricular Ejection Fraction 51
Impact of SGLT2 inhibitors on endothelial function and echocardiographic parameters in dilated cardiomyopathy 50
Acute Heart Failure: Transitioning From Symptom-Based Care to Remission 50
Lactate Values and Mortality in Patients With Cardiogenic Shock: Insights From the Altshock-2 Registry 49
Increasing Evidence Supports the Benefits of Rapid Uptitration of the Neurohormonal Blockade in HFmrEF/HFpEF Patients With AHF 49
Is it NICE to measure natriuretic peptides after a hospitalization for heart failure? 48
Role of ejection fraction in patients at risk for advanced heart failure: insights from the HELP-HF registry 48
Pre-admission beta-blocker therapy and outcomes in cardiogenic shock: Insights from the Altshock-2 Registry 48
Early changes in renal function during rapid up-titration of guideline-directed medical therapy following an admission for acute heart failure 48
February 2021 at a glance: focus on amyloidosis, myocarditis and cardiomyopathy 47
Effects of Rapid Uptitration of Neurohormonal Blockade on Effective, Sustainable Decongestion and Outcomes in STRONG-HF 47
Differences between cardiogenic shock related to acute decompensated heart failure and acute myocardial infarction 47
Effects of anti-inflammatory therapy in acute heart failure: a systematic review and meta-analysis 47
Insights on prevalence and incidence of anemia and rapid up-titration of oral heart failure treatment from the STRONG-HF study 46
Noncardiac comorbidities and intensive up-titration of oral treatment in patients recently hospitalized for heart failure: insights from the STRONG-HF trial 46
Aetiological phenotypes of atrial and ventricular secondary tricuspid regurgitation and their prognostic implications: insights from the CARE-TR registry 45
Frequency, characteristics and risk assessment of pulmonary arterial hypertension with a left heart disease phenotype 45
Socio-economic status and the effect of guideline-directed medical therapy in the STRONG-HF study 43
Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure in elderly patients: a sub-analysis of the STRONG-HF randomized clinical trial 43
Ejection fraction in heart failure: just become Emperor's new clothes? 43
Phenotype and outcomes according to loop diuretic use in pulmonary arterial hypertension 42
Impact of Rapid Up-Titration of Guideline-Directed Medical Therapies on Quality of Life: Insights From the STRONG-HF Trial 41
Safety Indicators in Patients Receiving High-intensity Care After Hospital Admission for Acute Heart Failure: The STRONG-HF Trial 40
Corticosteroid burst therapy in patients with acute heart failure: Design of the CORTAHF pilot study 40
Totale 6.448
Salva come PNG Salva come JPEG
Categoria #
all - tutte 40.803
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.803
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202236 0 0 0 0 2 1 2 0 2 0 3 26
2022/2023206 23 21 4 6 15 56 2 16 26 1 13 23
2023/2024622 27 11 52 33 30 71 42 17 150 21 43 125
2024/20251.864 13 22 81 152 144 140 203 94 161 225 370 259
2025/20264.128 440 595 355 677 411 282 527 228 346 267 0 0
Totale 6.856